Sun Pharma's ANDA Acceptance Signals Competitive Shift in Cough Suppressant Market
Neurology · Cough Suppressant • Regulatory Approval • Jun 21, 2026
Assessment confidence: 68% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.
Executive Thesis
The FDA's acceptance of Sun Pharma's ANDA for Dextromethorphan Hydrobromide and Quinidine Sulfate signifies a potential shift in the competitive landscape of the cough suppressant market. Portfolio teams must evaluate the implications for market share and strategize accordingly to mitigate risks from increased competition. Regulatory context from FDA (FDA AP — DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE (ORIG)) supports the near-term read. Assessment grounded in 9 ranked evidence items (5 high-relevance).
Strategic Assessment
Portfolio teams should assess the impact of this approval on market dynamics and consider strategies to counteract potential market share loss. The strongest clinical anchor is HFCWO Vest Plus Mechanical Cough Assist Versus Cough Assist Alone on Respiratory Infections in ALS: Pilot Trial (ClinicalTrials.gov), mechanism alignment (io ). In rare disease, 6 regulatory and 1 competitive items passed relevance filtering for Sun Pharma.
Competitive Pressure
The most relevant competitive pressure comes from FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment (Humanexa Signals) — sponsor/company relevance (roche). This acceptance may enhance Sun Pharma's position in the cough suppressant market, potentially increasing competition against existing products.
Regulatory Outlook
Regulatory risk is concentrated around FDA AP — DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE (ORIG) (FDA). Sub-indication match (rare disease); Regulatory pathway relevance (nda). While the ANDA acceptance is a positive step for Sun Pharma, the timeline for final approval and subsequent market entry remains critical for assessing regulatory impacts on the competitive landscape.
Key Risks
- Elevated medium regulatory exposure for Sun Pharma could delay market entry or constrain labeling if agency review intensifies.
Key Opportunities
- Sun Pharma's entry into the market could disrupt existing players, affecting their revenue and market positioning. Companies must prepare for potential price competition and shifts in consumer preference.
- Upside for Sun Pharma may improve if A Study to Investigate the Effect of AZD6234, AZD9550, and Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Part (ClinicalTrials.gov) delivers favorable follow-through.
- Portfolio teams should assess the impact of this approval on market dynamics and consider strategies to counteract potential market share loss.
What Would Change This Assessment
- This becomes more urgent if Monitor the timeline for final approval and market entry, as well as competitor responses.
- Timeline shift beyond mid term would change urgency.
- A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.
Supporting Evidence
FDA AP — DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE (ORIG)
FDAhigh relevance
Sub-indication match (rare disease); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — DEXTROMETHORPHAN POLISTIREX (ORIG)
FDAhigh relevance
Sub-indication match (rare disease); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — DEXTROMETHORPHAN POLISTIREX (ORIG)
FDAhigh relevance
Sub-indication match (rare disease); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — AUVELITY (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — AUVELITY (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease); Regulatory pathway relevance (nda)
FDA document
View sourceLessons Learned from our Roundtable with Rare Disease Advocates
FDAmedium relevance
Sub-indication match (rare disease)
FDA document
View sourceFDA AP — ATROPINE SULFATE (SUPPL)
FDAlow relevance
Regulatory pathway relevance (nda)
FDA document
View source
HFCWO Vest Plus Mechanical Cough Assist Versus Cough Assist Alone on Respiratory Infections in ALS: Pilot Trial
ClinicalTrials.govmedium relevance
Mechanism alignment (IO )
FDA document
View sourceA Study to Investigate the Effect of AZD6234, AZD9550, and Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Part
ClinicalTrials.govmedium relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View sourceEvaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceAssessment of the Efficacy of Highly Standardized Ginger and Perilla Nutraceutical (Dispepril®) in Improving Gastric and Intestinal Symptoms in Patients With Functional Dyspepsia
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceA 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough - China Extension
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
No evidence in this category.
Lavandula angustifolia as a dual pharmacological system: from essential oil to polyphenol-rich biomass.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceULK1's role in cancer progression and its emerging therapeutic potential.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Related Signals
Related Regulatory Precedents
FDA
FDA AP — ATROPINE SULFATE (SUPPL)
Application ANDA218148. Sponsor: MANKIND PHARMA. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: ATROPINE SULFATE.
SourceFDA
FDA AP — AUVELITY (SUPPL)
Application NDA215430. Sponsor: AXSOME. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: BUPROPION HYDROCHLORIDE, DEXTROMETHORPHAN HYDROBROMIDE.
SourceFDA
FDA AP — DEXTROMETHORPHAN POLISTIREX (ORIG)
Application ANDA218417. Sponsor: AUROBINDO PHARMA LTD. Submission status: AP. Submission type: ORIG. Review priority: STANDARD. Active ingredients: DEXTROMETHORPHAN POLISTIREX.
SourceFDA
FDA AP — AUVELITY (SUPPL)
Application NDA215430. Sponsor: AXSOME. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: BUPROPION HYDROCHLORIDE, DEXTROMETHORPHAN HYDROBROMIDE.
SourceFDA
S9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and Answers
Source